Phio Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 9
- Market Cap
- $2.7M
- Website
- http://www.phiopharma.com
- Introduction
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Intratumoral PH-762 for Cutaneous Carcinoma
- Conditions
- Squamous Cell Carcinoma of the SkinMerkel Cell Carcinoma of SkinMalignant Melanoma of Skin
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Phio Pharmaceuticals Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06014086
- Locations
- 🇺🇸
Paradigm Clinical Research, San Diego, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Integrity Research, Delray Beach, Florida, United States
News
Phio Pharmaceuticals' PH-762 Shows Complete Tumor Clearance in Skin Cancer Trial
Phio Pharmaceuticals reports two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance in a Phase 1b trial of PH-762.
Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 for Skin Cancers
Phio Pharmaceuticals has completed enrollment in the second cohort of its Phase 1b dose-escalating clinical trial of PH-762.
Phio Pharmaceuticals' INTASYL Platform Enhances Immune Cell Targeting of Cancer
Phio Pharmaceuticals announced data showcasing its INTASYL siRNA technology's ability to enhance immune cell targeting and killing of cancer cells.